Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (13)

1

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

2

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

3

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

enthalten in: Molecular cancer therapeutics | 2013

von Batey, M. | Zhao, Y. | Kyle, S. | +6

4

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

enthalten in: Molecular cancer therapeutics | 2012

von Munck, J. | Batey, M. | Zhao, Y. | +15

5

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

enthalten in: Molecular cancer therapeutics | 2011

von Ali, M. | Kamjoo, M. | Thomas, H. | +6

6

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

enthalten in: Molecular cancer therapeutics | 2009

von Thomas, H. | Saravanan, K. | Wang, L. | +8

7

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

enthalten in: Molecular cancer therapeutics | 2009

von Clarke, M. | Mulligan, E. | Grogan, P. | +9

8

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

enthalten in: Molecular cancer therapeutics | 2009

von Clarke, M. | Mulligan, E. | Grogan, P. | +9

9

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

enthalten in: Molecular cancer therapeutics | 2009

von Thomas, H. | Saravanan, K. | Wang, L. | +8

10

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

enthalten in: Molecular cancer therapeutics | 2007

von Thomas, H. | Calabrese, C. | Batey, M. | +9